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Abstract
Background: Attention-deficit hyperactivity disorder (ADHD) is a chronic condition and pharmacotherapy is the mainstay of
treatment, with a variety of ADHD medications available to patients. However, it is unclear to what extent the long-term
safety and efficacy of ADHD drugs have been evaluated prior to their market authorization. We aimed to quantify the
number of participants studied and their length of exposure in ADHD drug trials prior to marketing.
Methods: We identified all ADHD medications approved by the Food and Drug Administration (FDA) and extracted data on
clinical trials performed by the sponsor and used by the FDA to evaluate the drug’s clinical efficacy and safety. For each
ADHD medication, we measured the total number of participants studied and the length of participant exposure and
identified any FDA requests for post-marketing trials.
Results: A total of 32 clinical trials were conducted for the approval of 20 ADHD drugs. The median number of participants
studied per drug was 75 (IQR 0, 419). Eleven drugs (55%) were approved after ,100 participants were studied and 14 (70%)
after ,300 participants. The median trial length prior to approval was 4 weeks (IQR 2, 9), with 5 (38%) drugs approved after
participants were studied ,4 weeks and 10 (77%) after ,6 months. Six drugs were approved with requests for specific
additional post-marketing trials, of which 2 were performed.
Conclusions: Clinical trials conducted for the approval of many ADHD drugs have not been designed to assess rare adverse
events or long-term safety and efficacy. While post-marketing studies can fill in some of the gaps, better assurance is
needed that the proper trials are conducted either before or after a new medication is approved.
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Introduction
As many as 10% of children and adolescents in the United
States carry a diagnosis of attention-deficit hyperactivity disorder
(ADHD), making it one of the most common conditions of
childhood. [1,2] The single most efficacious treatment for reducing
symptoms of ADHD are medications and most children diagnosed
with ADHD receive pharmacotherapy. [1,3,4] Clinicians and
patients have a large therapeutic armamentarium to choose from,
with over a dozen ADHD medications marketed in a wide array of
formulations and delivery systems [5].
The short-term therapeutic response to ADHD medications is
upwards of 70%, among the highest of psychiatric medications.
[6,7] As a result, although ADHD typically requires long-term
treatment, the short-term efficacy of ADHD drugs can be assessed
after a brief treatment period, often on the order of days to weeks
[6].
Since most trials focus on efficacy measures as primary
endpoints, clinical trials testing ADHD medications may be
relatively short, resulting in drugs with limited long-term safety or
efficacy data. [8] Further, since studies are powered to measure
efficacy endpoints, sample sizes may be inadequate to detect rare
adverse events related to ADHD medications [7].
Guidelines for the safety and efficacy evaluation of drugs are
provided by the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH). [9] Though not binding, these requirements
guide clinical trial practice by the United States Food and Drug
Administration (FDA). [10] The ICH provides specific recom-
mendations on the safety assessment of chronic drugs used in the
treatment of non-life-threatening conditions, which includes
ADHD. [11] The guideline states that since most adverse drug
events first occur and are most frequent during the initial months
of treatment, approximately 300 to 600 patients should be treated
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e102249
for at least 6 months prior to market availability. Some adverse
events may increase in frequency or severity over time or may only
occur after several months of treatment; therefore, at least 100
patients should be exposed to a drug for at least 12 months. And
finally, the guidelines recommend that the total number of patients
treated with a medicine prior to approval, including short-term
exposure, should be about 1500.
To assess the extent to which rare adverse events and the long-
term safety and efficacy of ADHD drugs have been evaluated prior
to their market authorization, we sought to identify and evaluate
all safety and efficacy trials submitted to the FDA for the approval
of ADHD drugs and quantify the number of participants studied
and their length of exposure prior to the market availability of
each ADHD medicine. We hypothesized that the premarket study
of many ADHD medications in children has been insufficient to
adequately assess rare adverse events and long-term safety and
efficacy.
Methods
Drugs Used in the Treatment of ADHD
We identified all drugs approved by the FDA for ADHD using
information available on the FDA website as well as other online
resources. [12,13] All products with a unique NDA number were
selected. We recorded the drugs’ FDA approval date for the
indication of ADHD, the approved ages for treatment, the drug
formulation, the pharmaceutical company sponsoring the appli-
cation, and the current marketing status of the drug. When there
was no FDA approval date for ADHD, we used the date of the first
label on which ADHD was listed as an indication for the drug
(N= 2).
Data Sources and Extraction
For each drug identified, we obtained the FDA Drug Approval
Package, which includes the medical and statistical reviews,
approval letters, drug labels, and any related administrative
documents and correspondence. For newer agents, these docu-
ments are posted on the FDA website. [13] When the approval
packages were not available, they were obtained from the FDA
through a Freedom of Information Act request.
We reviewed the approval documents and identified the clinical
trials performed by the sponsor and used by the FDA to evaluate
the drug’s clinical efficacy or safety in the review process. If the
agent was not a New Molecular Entity (and thus prior trials and
FDA review had been performed), we reviewed the clinical trials in
the original FDA approval package in order to identify any
pediatric patients who may have been studied in safety or efficacy
assessments. Thus, for drugs representing new formulations or
drugs repurposed for the indication of ADHD and for which the
FDA approval process might be modified and possibly less
stringent given the prior review, we analyzed all clinical trials
that had been conducted for approval at any stage. Several drugs
had FDA approvals that either recommended or required the
conduct of additional, post-marketing clinical trials. When the
approval packages did not include supplemental information on
these trials, we searched the online trial registry ClinicalTrials.gov
to determine whether additional trials had been performed. We
also contacted the pharmaceutical companies who had sponsored
the drug applications to inquire about clinical trials performed in
response to the FDA requests.
For each medication we extracted the following information:
number of clinical trials supporting the application, number of
participants studied who received at least one dose of the study
drug, participant age ranges, trial duration at dosage levels
intended for clinical use (i.e. excluding open-label titration
periods), and comparators (if any) employed. Trials were
categorized as efficacy or safety trials, with safety trials defined
as those explicitly labeled as safety by the sponsor.
The clinical trials related to the drug approvals were linked to
publications in the medical literature with a search of PubMed.
Trials and publications were matched on the drug name, trial
design characteristics, number of participants, and trial duration
[14].
Data Analysis
Descriptive statistics were used to report the total number of
participants studied for less than 6 months, for at least 6 months,
and for at least 12 months. Since many drugs used in the treatment
of ADHD have been on the market for many years and the FDA
approval process may have evolved over this period, we also
calculated these values for the drugs approved in the last 10 years
(since 2004).
Results
We identified 20 drugs approved by the FDA via a New Drug
Application (NDA) for the treatment of ADHD in children
(Table 1). These drugs represent 10 different active ingredients
with the individual products differing based on the formulation
and delivery systems. Most drugs were approved for children 6
years and older with two drugs approved for children as young as
3 years old. Only 3 of the drugs have been discontinued. Original
drug approval packages were not available on the FDA website
and therefore obtained via a Freedom of Information Act (FOIA)
request for Ritalin, Ritalin SR, Desoxyn, Cylert, Dexedrine,
Biphetamine, Adderall, and Adderall XR.
Characteristics of Clinical Trials
There were 32 clinical trials conducted by sponsors prior to the
initial FDA approval of the ADHD drugs. Of these, 5 studies–
representing 3 drugs–were safety studies. The minimum age of
participants in all of the trials was 6 years. Six of the drugs were
studied in efficacy trials that included an active comparator (5
included both an active comparator and placebo) while all others
were approved based on comparison to placebo alone. Among the
10 most recently approved drugs, only 2 included comparison to
one of the ADHD drugs already marketed. A total of 8 (25%) of
the trials have been published in the medical literature.
Number of Participants and Length of Study
The median number of participants studied per drug was 75
(IQR 0, 419; range 0 to 660). Overall, 2756 (66%) participants
were studied for less than 6 months, 746 (18%) for 6 to 11 months,
and 688 (16%) for 12 or more months (Table 2).
Seven drugs were approved by the FDA for the treatment of
ADHD without the submission of any clinical trial data by the
sponsors. Of these, 5 were approved between 1943 and 1975, one
(Adderall) in 1996 and another (Methylin) in 2003. Ritalin, the
oldest drug approved for ADHD, was approved based on prior
clinical experience, which was presented as a bibliography.
Methylin was a new formulation of previously approved methyl-
phenidate that underwent an NDA but without the submission of
pediatric efficacy trials. [15] Desoxyn was originally approved in
1943 as an anorectic in the treatment of obesity but no clinical
trials assessing its safety in children or its efficacy in the treatment
of ADHD in children were identified in the original approval
package. The indication for ADHD is first included on the drug
label in 1965 without supporting clinical trials in the accompa-
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nying documentation. The approval package for Cylert includes
information on pre-clinical trials without mention of clinical trials
conducted for any indication. Dexedrine was approved for the
treatment of narcolepsy, obesity, and ADHD, but the approval
package does not include trials enrolling children or studying
efficacy for ADHD. Similarly, Biphetamine was previously
approved as an anorectic in adults, but the original approval
package does not include safety assessments in children and
ADHD was added as an indication in product labels starting in
1979 without supporting clinical trials. Adderall was originally
approved in 1960 as an anorectic under the trade name Obetrol
before being marketed without FDA approval as Adderall for the
treatment of ADHD. Approval was subsequently obtained without
clinical trials assessing its safety in children or efficacy in ADHD
[16].
Among the 13 drugs with clinical trials studying ADHD, a total
of 4 drugs (31%) were approved after less than 100 participants
had been studied while 7 drugs (54%) were approved after study in
Table 1. Medications approved by the FDA for the treatment of ADHD.
Active ingredient Brand namea
FDA approval
dateb
Approved
ages for
use
Formulation
and delivery
system
Pharmaceutical company
sponsoring application Marketing status
Stimulants
Methylphenidate
hydrochloride
Ritalin 12/5/1955 6 years and
older
Oral tablet Novartis Prescription
Ritalin SR 3/30/1982 6 years and
older
Oral extended-release
tablet
Novartis Prescription
Concerta 8/1/2000 6 years and
older
Oral extended-release
tablet, OROS
Janssen Pharms Prescription
Metadate CD 4/3/2001 6 years and
older
Oral extended-release
capsule
UCB Inc. Prescription
Ritalin LA 6/5/2002 6 years and
older
Oral extended-release
capsule, SODAS
Novartis Prescription
Methylin 12/19/2002 4/15/2003 6 years and
older
Oral solution Oral
chewable tablet
Mallinckrodt Prescription
Daytrana 4/6/2006 6 years and
older
Transdermal
extended-release film
Noven Pharms Prescription
Quillivant XR 9/27/2012 6 to 17
years
Oral extended-release
suspension
Nextwave Pharms Prescription
Methamphetamine
hydrochloride
Desoxyn 1965c 12 years and
older
Oral tablet Lundbeck Prescription
Pemoline Cylert 1/27/1975 1/30/1976 6 years and
older
Oral tablet Oral
chewable tablet
Abbott Discontinued
Dextroamphetamine
sulfate
Dexedrine 8/2/1976 3 years and
older
Oral extended-release
capsule
Amedra Pharms Prescription
Amphetamine,
dextroamphetamine
mixed salts
Biphetamine 1979c 3 years and
older
Oral extended-release
capsule
UCB Inc. Discontinued
Adderall 02/13/1996 3 years and
older
Oral tablet Teva Womens Discontinued
Adderall XR 10/11/2001 6 years and
older
Oral extended-release
capsule
Shire Prescription
Dexmethylphenidate
hydrochloride
Focalin 11/13/2001 6 years and
older
Oral Tablet Novartis Prescription
Focalin XR 5/26/2005 6 years and
older
Oral extended-release
capsule, SODAS
Novartis Prescription
Lisdexamfetamine
dimesylate
Vyvanse 2/23/2007 6 to 12
years
Oral capsule Shire Prescription
Non-stimulants
Atomoxetine
hydrochloride
Strattera 11/26/2002 6 years and
older
Oral capsule Eli Lilly Prescription
Guanfacine
hydrochloride
Intuniv 9/2/2009 6 years and
older
Oral extended-release
tablet
Shire Prescription
Clonidine
hydrochloride
Kapvay 9/28/2010 6 years and
older
Oral extended-release
tablet
Shionogi Inc. Prescription
aAll drugs approved by the FDA under a New Drug Application (NDA).
bApproval date for treatment of ADHD.
cDate derived from first product labeling to include ADHD as an indication as the FDA approval package for biphetamine and desoxyn do not include ADHD as one of
the drug indications.
doi:10.1371/journal.pone.0102249.t001
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less than 300 participants. Efficacy trials ranged from 1 to 10
weeks and safety trials from 6 to 12 months in length. The median
trial length prior to approval was 4 weeks (IQR 2, 9; range 1 to 52
weeks), with 5 (38%) drugs approved after participants were
studied for less than 4 weeks, 7 (54%) after less than 8 weeks, and
10 (77%) after less than 6 months.
Focusing on the 6 drugs approved since 2004, the median
number of participants studied per drug was 259 (IQR 53, 517;
range 45 to 629) and there were 1309 (74%), 127 (7%), and 327
Table 2. Clinical trials conducted for the FDA approval of ADHD drugs in children.
Brand name
Number and type of
clinical trials
Participant age
ranges
Number of participants
studied and treated
Duration of trial and
follow up Comparator(s)
Trials
published
Desoxyn 0
Ritalin 0
Ritalin SR 3 efficacy unknown 48a 2 weeks Ritalin 0
Concerta 3 efficacy 6 to 12 years 64 1 week Placebo/Ritalin 0
70 1 week 1[30]
94 4 weeks 1[42]
1 safety 6 to 13 years 432b 6 months None 1[43]
Metadate CD 1 efficacy 6 years and older 158 3 weeks Placebo 0
Ritalin LA 2 efficacy 6 to 12 years 34 2 weeks Placebo 0
63
Methylin 0c
Daytrana 2 efficacy 6 to 12 years 79 1 week Placebo 0
96 2 weeks Placebo/Concerta 1[44]
2 safety 127b 6 months None 0
327b 1 year
Quillivant XR 1 efficacy 6 to 12 years 45 2 weeks Placebo 0
Cylert 0d
Dexedrine 0e
Biphetamine 0e
Adderall 0f
Adderall XR 2 efficacy 6 to 12 years 360 3 weeks Placebo 0
51 1 week Placebo/Adderall
Focalin 2 efficacy 6 to 17 years 43 4 weeks Placebo/Methylphenidate 0
35 20 weeks Placebo
2 safety 187b 6 months None 0
361b 1 year
Focalin XR 1 efficacy 6 to 17 years 53 7 weeks Placebo 0
Vyvanse 2 efficacy 6 to 12 years 50 1 week Placebo/Adderall 1[45]
213 4 weeks Placebo 1[46]
Strattera 4 efficacy 6 years and older 213 8 weeks Placebo 0
85 6 weeks
65 9 weeks
64 9 weeks
Intuniv 2 efficacy 6 to 17 years 259 8 weeks Placebo 1[47]
258 9 weeks 0
Kapvay 2 efficacy 6 to 17 years 154 8 weeks Placebo 1[48]
102 0
aAssumed equal distribution of randomized participants between the two study arms.
bNot all unique patients as some participants from efficacy trial subsequently enrolled in safety trial.
cMethylin was a new formulation of FDA-approved methylphenidate.
dFDA approval package includes information on pre-clinical trials only and there is no mention of the conduct of clinical trials.
eThe FDA approval package included clinical trials of Dexedrine and Biphetamine for the treatment of obesity in adults, but no clinical trials assessing their use for the
treatment of ADHD were identified.
fAdderall was originally approved in 1960 as an anorectic under the brand name Obetrol, but no clinical trials assessing their use for the treatment of ADHD were
identified.
doi:10.1371/journal.pone.0102249.t002
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(18%), participants studied for less than 6 months, 6 to 11 months,
and 12 or more months of study, respectively. The median trial
length prior to approval was 8 weeks (IQR 2, 20; range 1 to 52
weeks).
Based on the ICH guidelines for safety assessments of chronic
medications, none of the drugs met the recommendation for 1500
participants studied prior to drug approval (Table 3). Three of the
drugs, Daytrana, Focalin, and Concerta (15% of all ADHD drugs),
met requirements to have at least 300 participants total exposed to
the drug for 6 months prior to marketing. Daytrana and Focalin
(10% of all ADHD drugs) were also compliant with the
recommendation to study at least 100 participants for 12 months.
Clinical Trials Requested by the FDA
FDA approval of 4 of the drugs included required submission of
additional clinical trials by the sponsor and 2 drug approvals
included recommendations for additional trials (Table 4). The
basis for the required studies cited by the FDA included concerns
over limited long-term safety data, limited study in the adolescent
population, and insufficient information on specific potential
adverse events [17–19].
The sponsors for Daytrana and Kapvay conducted the required
studies, adhering to the timelines imposed by the FDA for study
completion. None of the studies required for Vyvanse or Intuniv or
any of the studies recommended for Ritalin or Focalin XR could
be identified. The corresponding pharmaceutical companies in
each of these cases were contacted and were also not able to
provide us with information that these trials had been conducted.
Discussion
This is the first systematic assessment of patient exposure to
ADHD medications prior to their approval and market availabil-
ity. A total of 17 medications are currently available in the U.S. for
the treatment of ADHD in children, 6 of which have been
approved by the FDA in the last 10 years. These drugs are
intended for chronic use in children, but the median trial length
prior to approval is 4 weeks and only 3 of the drugs have been
assessed in long-term safety trials. The number of exposed children
prior to approval is also small, with 14 drugs approved after study
in less than 300 participants. Concerta, Daytrana, and Focalin
(15% of all ADHD drugs) are the only drugs that meet the ICH
recommendations of at least 300 patients studied for 6 months
prior to market availability.
Concerns over the lack of safety data–including adverse events
and long-term safety issues–for ADHD drugs have been voiced by
a number of entities, including the FDA, the NIH, and the
European Committee for Medicinal Products for Human Use.
[17,20,21] Known adverse effects vary for the different drugs and
include growth retardation, decreased appetite, insomnia, and
cardiovascular effects. [6,22–24] Post-marketing reports of adverse
events prompted the FDA in 2007 to require manufacturers of
drugs approved for the treatment of ADHD to develop
Medication Guides with detailed information for clinicians and
parents on possible adverse effects and precautions that can be
taken to avoid them. [25,26] Package inserts of all stimulant drugs
for the treatment of ADHD have also been amended to include
warning language around specific risks. [7].
Because ADHD is a chronic condition, the long-term efficacy of
ADHD drugs also warrants further consideration. [8,20] Long-
term follow up studies of children treated with ADHD medications
have not been designed to adequately assess the long-term benefits
of medication therapy compared to behavioral interventions. [27],
[28] One prospective 8-year follow-up study of children with
ADHD who had been treated for at least 14 months with
medication indicated there may be no advantage in academic
performance or social functioning in children who received
medication compared to those managed with behavioral inter-
ventions. [28] Additional long-term studies are needed assessing
the impact of ADHD treatments into adolescence and of outcome
measures beyond ADHD symptoms that capture effects on long-
term functioning.
In order for drugs to become available in a timely fashion, large
long-term randomized controlled trials may not always be feasible.
Instead, post-marketing observational trials can provide additional
information on rare adverse events and better delineate a drug’s
long-term safety and efficacy. [29] In the European Union,
pharmaceutical companies seeking market authorization for a
drug must submit a Risk Management Plan with detailed
proposals for post-authorization pharmacovigilence activities and
efficacy studies. [30,31] These management plans are considered
continuous, evolving processes and can be modified at the request
of regulatory agencies as new information–including safety
concerns–become available [32,33].
In the U.S., the FDA historically relied on studies referred to as
‘‘post-marketing commitments’’ to obtain additional safety and
efficacy data after a drug was approved. [34] These commitments
were agreed upon by the FDA and the pharmaceutical companies
at the time of approval and were often mandated as a condition for
approval. However, the FDA lacked any avenues for enforcement,
and reports showed that as many as two-thirds of requested studies
were never started by the pharmaceutical companies. [35,36] The
FDA Amendments Act of 2007 granted the FDA additional
authority to require post-marketing studies–now referred to as
‘‘post-marketing requirements’’–and also expanded the conditions
under which the FDA could make the requests. [37] The FDA
may now take enforcement action to ensure studies are conducted
and recent reports have shown substantial improvement in
compliance with study requests [38].
While we found poor compliance with post-marketing study
requests for ADHD drugs, moving forward, these studies may
represent an important tool for the detection of rare adverse events
Table 3. Compliance of pre-approval ADHD clinical drug trials with ICH guidelines overall and during past 10 years.
Time period
300 participants exposed for at least 6
months, N (%)
100 participants exposed for at least 12
months, N (%)
1500 participants exposed in
total
Drugs approved pre-2004
(N = 14)
2 (14) 1 (7) 0
Drugs approved 2004 to 2013
(N = 6)
1 (17) 1 (17) 0
All drugs (N = 20) 3 (15) 2 (10) 0
doi:10.1371/journal.pone.0102249.t003
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and the long-term safety and efficacy of medications. However,
observational studies are not equivalent to randomized controlled
trials powered to detect adverse events or specific efficacy end-
points, nor can they approximate the rigor of randomized trials in
accounting for treatment selection bias and other design issues.
[39] Instead, post-marketing observational studies should comple-
ment pre-approval clinical trials, designed to include sufficient
patient exposure to reasonably assess specific long-term safety and
efficacy measures. As such, it is critical that we re-evaluate current
standards in pre-approval trials and the exposure of patients to a
new drug prior to its approval [40].
Three-arm trials, including the experimental drug, an active
reference treatment, and a placebo comparator, are recommended
by the ICH and by the European Medicines Agency specifically
for the clinical investigation of ADHD drugs. [20,41] Three-arm
trials serve two main purposes. First, the placebo comparator
provides internal trial validation and demonstrates superiority of
both drugs to the placebo control. Secondly, comparison of the
new drug to an acknowledged standard yields comparative data on
the safety and efficacy profiles of new drugs to other agents already
available. We identified only 6 ADHD drugs that had been studied
in comparison to another drug, indicating that ADHD drugs are
introduced to the market with very little comparative data to guide
clinicians on the new drug’s effectiveness in the context of all
available options.
One of the limitations of this study is that, in some instances, the
records from the FDA may have been incomplete. For each of the
drugs, however, we were able to obtain the original approval
packages. Given that many of these agents have been on the
market for decades, there may be additional safety and efficacy
information that has emerged in studies conducted after the
original FDA approval. Nonetheless, our findings reflect the
studies required in the FDA approval process, including the trials
for a number of recently approved medications. Finally, our study
was limited to ADHD drugs and additional study is needed to
determine whether the FDA approval process is similar for other
drug classes used in pediatric patients.
In conclusion, clinical trials conducted for the approval of many
ADHD drugs have not been designed to assess rare adverse events
or long-term safety and efficacy. Despite the large number of
available drugs, comparative effectiveness trials are rare. While
post-marketing studies can fill in some of the gaps, FDA
enforcement is important to ensure that post-market surveillance
studies are completed. An ambitious agenda to assess long-term
outcomes in the millions of patients on these medications is
warranted.
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